ArticleLeukemia2009

CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.

A Takeshita et al.PubMed ↗Publisher ↗

No numbers read from the abstract.